Get the Stockscreener App
68.07
2.45%
1.60
Arrowhead Pharmaceuticals Inc stock is traded at $68.07, with a volume of 391.17K.
It is up +2.45% in the last 24 hours and up +74.75% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
See More
Previous Close:
$66.47
Open:
$66.52
24h Volume:
391.17K
Relative Volume:
0.16
Market Cap:
$9.24B
Revenue:
$181.74M
Net Income/Loss:
$-143.97M
P/E Ratio:
-48.97
EPS:
-1.39
Net Cash Flow:
$9.60M
1W Performance:
-2.84%
1M Performance:
+74.75%
6M Performance:
+335.98%
1Y Performance:
+249.23%
1-Day Range:
$65.70
$68.60
1-Week Range:
$59.51
$70.51
52-Week Range:
$9.57
$72.36
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
68.03 | 9.03B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.45 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.52 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.67 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
859.73 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.24 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Will Arrowhead Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Trade Ideas & AI Forecast Swing Trade Picks - DonanımHaber
Behavioral Patterns of ARWR and Institutional Flows - news.stocktradersdaily.com
Trading Action: Can Arrowhead Pharmaceuticals Inc. stock attract ESG capital inflowsGap Down & Detailed Earnings Play Strategies - moha.gov.vn
Can Arrowhead Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Movers & AI Powered Trade Plan Recommendations - Улправда
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given New $100.00 Price Target at Piper Sandler - MarketBeat
Piper Sandler Raises Arrowhead Pharma (ARWR) Price Target to $100 | ARWR Stock News - GuruFocus
Piper Sandler raises Arrowhead Pharma stock price target to $100 on Redemplo launch - Investing.com UK
ARWR (Arrowhead Pharmaceuticals) 12-1 Month Momentum % : 84.44% (As of Dec. 17, 2025) - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 54,298 Shares - MarketBeat
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Sells 130,000 Shares of Stock - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching - ts2.tech
Arrowhead (ARWR) Experiences Notable Decline in Share Price - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 7.6%What's Next? - MarketBeat
Arrowhead (ARWR) Sees Significant Decline as Stock Drops Over 12% - GuruFocus
Hudson Bay Capital Management LP Purchases 46,870 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
36,469 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Marex Group plc - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approval, Plozasiran Breakthrough Status and ARO-MAPT Trial Progress - Sahm
WINTON GROUP Ltd Invests $660,000 in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics - MSN
RBC Capital Maintains Arrowhead Pharmaceuticals (ARWR) Outperform Recommendation - Nasdaq
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 7th Annual CNS Delivery SummitSlideshow - Seeking Alpha
Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025 - ts2.tech
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Arrowhead Pharma (ARWR) Receives Raised Price Target from RBC Ca - GuruFocus
Arrowhead Pharmaceuticals stock hits 52-week high at 71.62 USD By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals stock hits 52-week high at 71.62 USD - Investing.com
Arrowhead Pharma stock price target raised to $80 from $52 at RBC Capital - Investing.com Canada
RBC Raises Price Target on Arrowhead Pharmaceuticals to $80 From $52, Keeps Outperform, Speculative Risk - marketscreener.com
Arrowhead Pharmaceuticals (ARWR) Valuation Check as ARO-MAPT Enters First Human Trial in Alzheimer’s Treatment - Yahoo Finance
History Review: Can Arrowhead Pharmaceuticals Inc stock surprise with earnings upsideJuly 2025 Closing Moves & Verified Momentum Stock Watchlist - moha.gov.vn
Michael Perry Sells 16,250 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock - MarketBeat
B of A Securities Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation - Nasdaq
ARWR: B of A Securities Raises Price Target Amid Maintained Buy Rating | ARWR Stock News - GuruFocus
Bank of America Issues Positive Forecast for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap DownTime to Sell? - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial - ts2.tech
Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval - MSN
Arrowhead Pharmaceuticals Flourishes with Key Milestones and Growth Projections - StocksToTrade
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins - ts2.tech
Arrowhead Pharmaceuticals stock soars after dosing first subjects in trial By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals stock soars after dosing first subjects in trial - Investing.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 1-Year HighTime to Buy? - MarketBeat
Arrowhead Hits the Mark - Los Angeles Business Journal
Arrowhead’s Plozasiran Garners FDA Breakthrough Recognition - timothysykes.com
Arrowhead (ARWR) Begins Trials for Alzheimer's Treatment - GuruFocus
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies - Business Wire
Marshall Wace LLP Grows Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Norges Bank Invests $30.41 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
(ARWR) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):